Aratana Therapeutics Company Profile (NASDAQ:PETX)

About Aratana Therapeutics

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PETX
  • CUSIP:
Key Metrics:
  • Previous Close: $9.36
  • 50 Day Moving Average: $9.15
  • 200 Day Moving Average: $7.12
  • 52-Week Range: $2.56 - $9.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.43
  • P/E Growth: -0.81
  • Market Cap: $331.48M
  • Outstanding Shares: 35,415,000
  • Beta: 3.79
Profitability:
  • Net Margins: -166.67%
  • Return on Equity: -17.53%
  • Return on Assets: -12.31%
Debt:
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 5.38%
  • Quick Ratio: 5.26%
Additional Links:
Companies Related to Aratana Therapeutics:

Analyst Ratings

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $11.86 (26.68% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
Show:
DateFirmActionRatingPrice TargetDetails
9/6/2016Lake Street CapitalReiterated RatingBuy$15.00View Rating Details
8/19/2016Jefferies GroupInitiated CoverageBuy$12.00 -> $13.00View Rating Details
8/17/2016William BlairReiterated RatingOutperformView Rating Details
8/11/2016Barclays PLCLower Price TargetOverweight$15.00 -> $11.00View Rating Details
8/10/2016Credit Suisse Group AGReiterated RatingBuy$11.00View Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00View Rating Details
3/16/2016Stifel NicolausLower Price TargetBuy$12.00 -> $11.00View Rating Details
11/4/2015Piper Jaffray Cos.Reiterated RatingOverweight$25.00 -> $15.00View Rating Details
2/25/2015JMP SecuritiesSet Price TargetBuy$38.00View Rating Details
2/25/2015Bank of America Corp.Boost Price Target$26.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Aratana Therapeutics (NASDAQ:PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)ViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-1.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.40)($0.41)
Q2 20162($0.43)($0.41)($0.42)
Q3 20164($0.43)($0.39)($0.41)
Q4 20163($0.47)($0.34)($0.40)
Q1 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 85.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.00View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
DateHeadline
thestreet.com logoShark Bites: Big Market Move May Be in the Making -- Clear the Decks! (NASDAQ:PETX)
realmoney.thestreet.com - September 28 at 6:29 PM
investornewswire.com logoCan Shares Of Aratana Therapeutics, Inc. (NASDAQ:PETX) Hit $18? - Investor Newswire (NASDAQ:PETX)
www.investornewswire.com - September 27 at 11:20 AM
News IconNews review of 2 biotech stocks: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Aratana Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PETX)
voiceregistrar.com - September 26 at 6:48 PM
realistinvestor.com logoAratana Therapeutics, Inc. (NASDAQ:PETX)'s Accounts Payable Is $7.272 - RealistInvestor.com (NASDAQ:PETX)
www.realistinvestor.com - September 24 at 6:03 PM
thestreet.com logoInteresting PETX Put And Call Options For May 2017 (NASDAQ:PETX)
www.thestreet.com - September 23 at 6:12 PM
News IconAratana Therapeutics, Inc. (NASDAQ:PETX) missed earnings on 2 occasions - The Independent Republic (NASDAQ:PETX)
theindependentrepublic.com - September 23 at 11:30 AM
News IconActive biotech company shares in the news: Aratana Therapeutics (NASDAQ:PETX), Seattle Genetics (NASDAQ:SGEN) - The Voice Registrar (NASDAQ:PETX)
voiceregistrar.com - September 23 at 11:30 AM
fool.com logoAre Investors Barking up the Wrong Tree With This Pure-Play Pet Stock? (NASDAQ:PETX)
www.fool.com - September 22 at 6:25 PM
News IconInstitutional Heat: Aratana Therapeutics INC (PETX) Stock Value Rose While Awm Investment Company INC Upped Its ... - Chester News (NASDAQ:PETX)
www.chesterindependent.com - September 21 at 10:48 AM
biz.yahoo.com logoARATANA THERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:PETX)
biz.yahoo.com - September 21 at 10:48 AM
publicnow.com logoAratana Therapeutics to Participate in Jefferies Animal Health Leadership Summit (NASDAQ:PETX)
www.publicnow.com - September 21 at 10:48 AM
News IconAnalysts Take: Aratana Therapeutics, Inc. (NASDAQ:PETX ... - Frisco Fastball (NASDAQ:PETX)
friscofastball.com - September 16 at 6:32 PM
News IconTime To Put On The Watch List? - Aratana Therapeutics, Inc. (NASDAQ:PETX), Arena Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PETX)
voiceregistrar.com - September 12 at 11:19 AM
News IconAnalysts Take the Wheel on Aratana Therapeutics, Inc. (NASDAQ:PETX) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:PETX)
friscofastball.com - September 9 at 6:21 PM
News IconActive biotech company shares in the news: Aratana Therapeutics ... - The Voice Registrar (NASDAQ:PETX)
voiceregistrar.com - September 9 at 6:21 PM
News IconTime To Put On The Watch List? - Aratana Therapeutics, Inc. (NASDAQ:PETX), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:PETX)
voiceregistrar.com - September 9 at 11:29 AM
News IconHow Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August - Madison.com (NASDAQ:PETX)
host.madison.com - September 9 at 11:29 AM
thestreet.com logoAs Market Bears Feast, Opportunities Develop (NASDAQ:PETX)
realmoney.thestreet.com - September 9 at 11:29 AM
fool.com logoHow Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August (NASDAQ:PETX)
www.fool.com - September 9 at 7:55 AM
News IconLake Street Capital Reaffirms "Buy" Rating for Aratana Therapeutics Inc. (PETX) (NASDAQ:PETX)
myhealthbowl.com - September 8 at 10:34 AM
News IconAratana Therapeutics Inc 66.7% Potential Upside Now Implied by Lake Street (NASDAQ:PETX)
www.crcconnection.com - September 8 at 10:34 AM
News IconAratana Therapeutics' (PETX) Buy Rating Reaffirmed at Lake Street Capital (NASDAQ:PETX)
magseriesusa.net - September 8 at 10:34 AM
finance.yahoo.com logoAratana's Drug Pipeline Suggests Revenue Growth Could Continue For Years (NASDAQ:PETX)
finance.yahoo.com - September 6 at 6:53 PM
News Icon3 Things You Need to Know About Aratana Therapeutics Before Buying - Madison.com (NASDAQ:PETX)
host.madison.com - September 1 at 6:42 PM
biz.yahoo.com logoARATANA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta (NASDAQ:PETX)
biz.yahoo.com - September 1 at 9:53 AM
fool.com logo3 Things You Need to Know About Aratana Therapeutics Before Buying (NASDAQ:PETX)
www.fool.com - September 1 at 9:53 AM
thestreet.com logo4 Momentum Stocks You Should Watch Now (NASDAQ:PETX)
www.thestreet.com - August 30 at 6:41 PM
rttnews.com logoBiotech Stocks Facing FDA Decision In September (NASDAQ:PETX)
www.rttnews.com - August 30 at 10:05 AM
investing.com logo4 Stocks To Watch: CETX, HDSN, LMAT, PETX (NASDAQ:PETX)
www.investing.com - August 30 at 10:05 AM
capitalcube.com logoETF’s with exposure to Aratana Therapeutics, Inc. : August 25, 2016 (NASDAQ:PETX)
www.capitalcube.com - August 25 at 11:53 AM
thestreet.com logoOctober 21st Options Now Available For Aratana Therapeutics (PETX) (NASDAQ:PETX)
www.thestreet.com - August 23 at 11:12 AM
investornewswire.com logoAratana Therapeutics, Inc. (NASDAQ:PETX) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:PETX)
www.investornewswire.com - August 22 at 6:43 PM
4-traders.com logoAratana Therapeutics : Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics (NASDAQ:PETX)
www.4-traders.com - August 17 at 7:04 PM
News IconHome Biotech Stocks Aratana Therapeutics, Inc. | $PETX Stock | Shares Spike Up On FDA... - TickerTV News (press release) (NASDAQ:PETX)
ticker.tv - August 17 at 9:49 AM
News IconAratana Therapeutics Granted FDA Approval of NOCITA (bupivacaine liposome injectable suspension) (NASDAQ:PETX)
www.pressreleasepoint.com - August 16 at 6:56 PM
investornewswire.com logoWill Aratana Therapeutics, Inc. (NASDAQ:PETX) Hit $18 Price Target? - Investor Newswire (NASDAQ:PETX)
www.investornewswire.com - August 16 at 10:03 AM
streetinsider.com logoAratana Therapeutics (PETX) Announces FDA Approval of NOCITA - StreetInsider.com (NASDAQ:PETX)
www.streetinsider.com - August 16 at 10:03 AM
streetinsider.com logoAratana Therapeutics (PETX) Announces FDA Approval of NOCITA (NASDAQ:PETX)
www.streetinsider.com - August 15 at 7:08 PM
finance.yahoo.com logo4:34 pm Aratana Therapeutics granted FDA approval of NOCITA (NASDAQ:PETX)
finance.yahoo.com - August 15 at 7:08 PM
publicnow.com logoAratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) (NASDAQ:PETX)
www.publicnow.com - August 15 at 7:08 PM
finance.yahoo.com logoARATANA THERAPEUTICS, INC. Financials (NASDAQ:PETX)
finance.yahoo.com - August 13 at 6:27 PM
capitalcube.com logoETF’s with exposure to Aratana Therapeutics, Inc. : August 12, 2016 (NASDAQ:PETX)
www.capitalcube.com - August 12 at 6:56 PM
capitalcube.com logoAratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:PETX)
www.capitalcube.com - August 11 at 7:18 PM
News IconAratana Therapeutics Inc (NASDAQ:PETX): Power Of Breakout Alert , We Made 15% Profit In Swing Trading (NASDAQ:PETX)
www.marketnewscall.com - August 10 at 9:53 AM
News IconHealthcare Companies in Hotspot: Aratana Therapeutics, Inc. (NASDAQ:PETX), Mast Therapeutics, Inc. (NYSEMKT ... - TWN (NASDAQ:PETX)
thewellesleysnews.com - August 9 at 7:02 PM
News IconHC Stocks Vigilant: Mast Therapeutics Inc (NYSEMKT:MSTX ... - share market updates (press release) (NASDAQ:PETX)
sharemarketupdates.com - August 8 at 7:00 PM
fortune.com logoCurrent Aratana Therapeutics, Inc. (NASDAQ:PETX) PT Means Stock Is Worth Almost $15 - Review Fortune (NASDAQ:PETX)
reviewfortune.com - August 8 at 7:00 PM
News IconUnusual Healthcare Volume Gainers In Focus- Aratana Therapeutics (NASDAQ:PETX), Merck & Co (NYSE:MRK) - Seneca Globe (NASDAQ:PETX)
www.senecaglobe.com - August 8 at 11:28 AM
streetupdates.com logoAnalyst Rating Fluctuations to Observe: Zoetis Inc. (NYSE:ZTS) , Aratana Therapeutics, Inc. (NASDAQ:PETX) - Street Updates (NASDAQ:PETX)
www.streetupdates.com - August 8 at 11:28 AM
finance.yahoo.com logoAratana Therapeutics (PETX) Worth a Look: Stock Gains 6.2% (NASDAQ:PETX)
finance.yahoo.com - August 8 at 11:28 AM

Social

Aratana Therapeutics (NASDAQ:PETX) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff